September 2021, Vol 11, No 9

According to results from a recent study, balstilimab, an investigational PD-1 inhibitor, demonstrated meaningful and durable clinical activity in patients with recurrent or metastatic cervical cancer. These findings were presented by Cailin E. Joyce, MD, Director, Applied Technology, Agenus, Boston, MA, during the American Society of Clinical Oncology 2021 virtual annual meeting. Read Article ›


The addition of the tyrosine kinase inhibitor tucatinib (Tukysa) to trastuzumab (Herceptin) and capecitabine continued to improve overall survival (OS) and progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer, according to updated results from the pivotal HER2CLIMB trial. The findings were presented at the American Society of Clinical Oncology 2021 virtual annual meeting by lead investigator Giuseppe Curigliano, MD, PhD, Associate Professor, Medical Oncology, University of Milano, Italy. Read Article ›

Approximately 13% of patients with lung adenocarcinoma harbor the KRAS p.G12C mutation, which is associated with poor clinical outcomes. During the American Society of Clinical Oncology 2021 virtual annual meeting, Ferdinandos Skoulidis, MD, PhD, MRCP, Assistant Professor, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, provided updated results from the phase 2 component of the CodeBreaK 100 clinical trial Read Article ›

Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved pathologic complete response (pCR) rates versus chemotherapy alone in patients with resectable stage IB-IIIA non–small-cell lung cancer (NSCLC), according to final results from the CheckMate-816 clinical trial. Read Article ›

The advent of biologic drugs has had a significant impact on the management of patients with cancer. However, the high costs associated with these agents can hinder treatment access for many patients and place a significant burden on healthcare systems. As several biologics have come off patent over the past few years and more are expected to do so in the near future, biosimilars are poised to play an increasingly important role in reducing healthcare costs. Read Article ›

Sacituzumab govitecan (Trodelvy), a Trop-2 antibody and topoisomerase inhibitor, showed promising results in a small clinical trial of patients with metastatic TNBC. These findings provided the basis for accelerated FDA approval of this agent in April 2020 for the treatment of patients with metastatic TNBC who have received ≥2 previous therapies in the metastatic setting, with full approval contingent on the results of the confirmatory phase 3 ASCENT study (Bardia A, et al. N Engl J Med. Read Article ›

It is estimated that in 2020, there were 6.3 million cases and 3.3 million deaths globally of mouth, pharynx, larynx, esophageal, colon, rectum, liver, and breast cancer. These cancers have causal links to alcohol consumption. However, patterns of alcohol use continue to change over time across the world. With changes in alcohol consumption and more recent cancer incidence data, new estimates of the alcohol-attributable burden of cancer are needed. Read Article ›

Oropharyngeal cancer, which can develop at the base of the tongue, tonsils, and the middle part of the throat, is primarily caused by human papillomavirus (HPV) infection, the most common sexually transmitted virus and infection in the United States.1 Over the past 2 decades, cases of HPV-positive oropharyngeal squamous-cell carcinoma (OPSCC) have been increasing at an alarming rate among men in the United States.2,3 According to the American Cancer Society, approximately 54,000 cases of oropharyngeal and oral cavity cancer will be diagnosed in the United States in 2021, and more than 10,000 individuals will die from the disease.4 OPSCC is often diagnosed at an advanced stage, resulting in increased mortality and morbidity. Read Article ›

The majority of leadership opportunities currently available in the medical practice community require individuals to be responsible for the operations of previously established businesses and teams. As a result, new and seasoned leaders alike are often finding themselves facing unique challenges as they navigate the nuances of assuming leadership of existing practices. This transition can be equally challenging for the staff members. In this article, we offer some strategies you can use to facilitate the process. Read Article ›

Page 1 of 2

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive: